Stephen E. Goldstone is an Assistant Clinical Professor of Surgery at The Icahn School of Medicine at Mount Sinai and has a surgical practice in New York City. Dr. Goldstone has spoken at conferences around the world and has done extensive research on human papillomavirus (HPV). His work has been published in many prestigious medical journals and is currently involved in testing both prevention and treatment procedures for HPV. He is a past-president of the International Anal Neoplasia Society and a member of the AIDS Malignancy Consortium.
At the completion of this educational session, learners will:
- Be aware of the progression rates of AIN3 to invasive anal cancer.
- Know who is at risk for progression.
- Understand the problems of close follow-up for patients with AIN3.
- Appreciate the possible utility of HPV testing as a tool when screening for anal dysplasia.
This CME activity has approved for AMA PRA Category 1 Credit™
on October 15, 2019 and will terminate October 14, 2022.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Dr. Stephen E. Goldstone (Presenter) had the following personal financial relationships in the prior 12 months with manufacturers of the products or services that may be presented in this CME activity: Investigator for Merck, Antiva, Inovio, and Metronic; Speaker at Merck; Consultant to Merck, and THD America. Dr. Goldstone submitted his slides in advance for adequate peer review. And will support his presentation and clinical recommendations with the best available evidence from the medical literature.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.
To obtain CME credit for this PRN program, please visit the PRN Courses Page
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.